MX388231B - Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal. - Google Patents

Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.

Info

Publication number
MX388231B
MX388231B MX2017005126A MX2017005126A MX388231B MX 388231 B MX388231 B MX 388231B MX 2017005126 A MX2017005126 A MX 2017005126A MX 2017005126 A MX2017005126 A MX 2017005126A MX 388231 B MX388231 B MX 388231B
Authority
MX
Mexico
Prior art keywords
prognosis
diagnosis
kidney
compositions
methods
Prior art date
Application number
MX2017005126A
Other languages
English (en)
Other versions
MX2017005126A (es
Inventor
Joseph Anderberg
Jeff Gray
James Patrick Kampf
Thomas Kwan
Paul Mcpherson
Kevin Nakamura
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2017005126A publication Critical patent/MX2017005126A/es
Publication of MX388231B publication Critical patent/MX388231B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para controlar, diagnosticar, pronosticar y determinar los regímenes de tratamiento en sujetos que padecen de o que se sospecha que tienen lesión renal. En particular, la lesión se refiere al uso de ensayos que detectan uno o más de motivo C-C de quimiocina 16, motivo C-C de quimiocina 14, y receptor de proteína cinasa tirosina UFO como ensayos de biomarcador de diagnóstico y pronóstico en lesiones renales.
MX2017005126A 2014-10-20 2015-10-20 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal. MX388231B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462066313P 2014-10-20 2014-10-20
US201462066316P 2014-10-20 2014-10-20
US201462066310P 2014-10-20 2014-10-20
PCT/US2015/056462 WO2016064877A2 (en) 2014-10-20 2015-10-20 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
MX2017005126A MX2017005126A (es) 2017-09-15
MX388231B true MX388231B (es) 2025-03-19

Family

ID=55761743

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005126A MX388231B (es) 2014-10-20 2015-10-20 Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.

Country Status (13)

Country Link
US (2) US11333671B2 (es)
EP (2) EP3968022A1 (es)
JP (4) JP6792553B2 (es)
KR (1) KR102431003B1 (es)
CN (2) CN107003301B (es)
AU (2) AU2015336069B2 (es)
BR (1) BR112017008218A2 (es)
CA (1) CA2965153C (es)
EA (1) EA201790696A1 (es)
ES (1) ES2907551T3 (es)
MX (1) MX388231B (es)
PT (1) PT3210018T (es)
WO (1) WO2016064877A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968022A1 (en) 2014-10-20 2022-03-16 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2019008260A (es) * 2017-01-12 2020-01-27 Astute Medical Inc Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
US11346846B2 (en) 2017-02-06 2022-05-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP3732196A4 (en) 2017-12-28 2022-01-05 Astute Medical, Inc. ANTIBODIES AND ASSAYS FOR CCL14
JP7221985B2 (ja) * 2018-04-02 2023-02-14 ポトレロ メディカル，インコーポレイテッド 体液の排出および分析、並びに健康の評価のためのシステム
US12114978B2 (en) 2018-04-02 2024-10-15 Potrero Medical, Inc. Systems, devices and methods for draining and analyzing bodily fluids and assessing health
CA3141817A1 (en) * 2019-05-24 2020-12-03 Astute Medical, Inc. Methods for evaluation and treatment of renal injury based on c-c motif chemokine ligand 14 measurement
US20230290457A1 (en) * 2020-03-23 2023-09-14 Biocogniv Inc. Artificial intelligence medical device
GB2596142B (en) * 2020-06-19 2023-11-29 Secr Defence Methods and associated uses, kits and systems for assessing sepsis
EP4247395A4 (en) * 2020-11-18 2024-09-18 Astute Medical, Inc. Methods and compositions for treatment of renal injury and renal failure

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
JPH05504841A (ja) 1990-09-14 1993-07-22 バイオサイト・ダイアグノスティックス・インコーポレイテッド リガンドレセプター及びリガンドのコンプレックスに対する抗体及びリガンド―レセプターアッセーでのそれらの用途
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
WO1992018868A1 (en) 1991-04-10 1992-10-29 Biosite Diagnostics Incorporated Crosstalk inhibitors and their uses
ATE195808T1 (de) 1991-04-12 2000-09-15 Biosite Diagnostics Inc Neue konjugate und testverfahren für die gleichzeitige bestimmung von multiplen liganden
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6811773B1 (en) * 1993-12-22 2004-11-02 Human Genome Sciences, Inc. Human monocyte colony inhibitory factor (M-CIF) polypeptides
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
IL163547A0 (en) 2002-02-12 2005-12-18 Quark Biotech Inc Use of the axl receptor for diagnosis and treatment of renal disease
US20120064089A1 (en) * 2002-11-15 2012-03-15 Morehouse School Of Medicine Anti-cxcl16 and anti-cxcr6 antibodies for the prevention and treatment of cancer and cancer cell migration
US7833732B2 (en) 2005-07-21 2010-11-16 The John Hopkins University Acute renal injury
AU2006292203A1 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
WO2009038742A2 (en) 2007-09-20 2009-03-26 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for estimating risk of acute kidney injury
EP2262531A1 (en) * 2008-03-08 2010-12-22 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
NZ619918A (en) 2008-10-21 2015-04-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011017685A1 (en) * 2009-08-07 2011-02-10 Rules-Based Medicine, Inc. Methods and devices for detecting kidney transplant rejection
NZ630277A (en) * 2009-09-21 2015-02-27 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CA2779905A1 (en) * 2009-11-07 2011-05-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX340078B (es) * 2009-11-07 2016-06-24 Astute Medical Inc Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal.
US20120156701A1 (en) * 2009-12-20 2012-06-21 Joseph Anderberg Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20120123056A (ko) * 2009-12-20 2012-11-07 아스튜트 메디컬 인코포레이티드 신손상 및 신부전을 진단 및 예측하는 방법 및 조성물
EP2531620B1 (en) * 2010-02-05 2016-12-14 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011269847A1 (en) * 2010-02-26 2013-01-31 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2585827A4 (en) * 2010-06-23 2013-12-04 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
MX2013000220A (es) * 2010-06-23 2013-03-22 Astute Medical Inc Metodos y composiciones para diagnóstico y pronóstico de lesión renal e insuficiencia renal.
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2012136548A1 (en) 2011-04-04 2012-10-11 Universiteit Gent Biomarkers for acute kidney injury
TR201903235T4 (tr) * 2011-08-26 2019-03-21 Astute Medical Inc Böbrek hasari ve böbrek yetmezli̇ği̇ni̇n tanilanmasi ve prognozuna yöneli̇k metotlar ve bi̇leşi̇mler.
WO2013086359A1 (en) * 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2013096740A1 (en) * 2011-12-21 2013-06-27 Alere San Diego Inc. Methods and compositions for assigning likelihood of chronic kidney disease progression
EP2962109A4 (en) 2013-02-26 2016-12-07 Astute Medical Inc METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
EP3968022A1 (en) 2014-10-20 2022-03-16 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Also Published As

Publication number Publication date
MX2017005126A (es) 2017-09-15
US11333671B2 (en) 2022-05-17
CN107003301B (zh) 2019-11-01
CN107003301A (zh) 2017-08-01
EP3968022A1 (en) 2022-03-16
JP2021039112A (ja) 2021-03-11
EP3210018B1 (en) 2021-07-28
EP3210018A4 (en) 2018-06-20
JP2023052587A (ja) 2023-04-11
US20220236286A1 (en) 2022-07-28
KR20170084102A (ko) 2017-07-19
WO2016064877A3 (en) 2016-09-09
CA2965153A1 (en) 2016-04-28
CN110702921B (zh) 2024-02-06
JP2017533427A (ja) 2017-11-09
CA2965153C (en) 2023-10-24
EA201790696A1 (ru) 2017-10-31
US20180209990A1 (en) 2018-07-26
JP6792553B2 (ja) 2020-11-25
WO2016064877A2 (en) 2016-04-28
ES2907551T3 (es) 2022-04-25
PT3210018T (pt) 2021-10-04
AU2015336069B2 (en) 2021-11-25
AU2015336069A1 (en) 2017-05-25
JP2022046669A (ja) 2022-03-23
CN110702921A (zh) 2020-01-17
KR102431003B1 (ko) 2022-08-09
EP3210018A2 (en) 2017-08-30
JP7002623B2 (ja) 2022-02-10
BR112017008218A2 (pt) 2018-01-09
AU2022201130B2 (en) 2024-06-27
JP7217796B2 (ja) 2023-02-03
AU2022201130A1 (en) 2022-03-17
US12099067B2 (en) 2024-09-24

Similar Documents

Publication Publication Date Title
MX388231B (es) Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal.
MX394474B (es) Métodos de pronóstico para cáncer de vejiga sin invasión muscular y antagonistas para usarse en el tratamiento de lo mismo.
EP2539712A1 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MA40390A (fr) Procédés d'analyse impliquant des nanoparticules dissociables
BR112019004075A2 (pt) métodos para diagnosticar um indivíduo com suspeita de endometriose, para detectar mirna, para diagnosticar um indivíduo que apresenta sintomas de endometriose ou com suspeita de endometriose, para tratar um indivíduo com endometriose, para diagnosticar e tratar um indivíduo com suspeita de endometriose, para diagnosticar endometriose em um indivíduo, para diagnosticar ou prover um prognóstico para endometriose em um indivíduo e para monitorar uma resposta a um tratamento de endometriose em um indivíduo, e, kit.
MX2019008260A (es) Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
MX2016002423A (es) Composiciones y metodos de diagnostico para el tratamiento de glioblastoma.
BR112016016101A2 (pt) Métodos para determinar o estado do distúrbio inflamatório, para monitorar a progressão de uma doença inflamatória ou monitorar a eficácia de um tratamento, kit, e, uso da determinação da presença, ou do nível, de tesnacina-c citrulinada e/ou um ou mais fragmentos de tesnacina-c citrulinada e/ou de autoanticorpos com especificidade para os mesmos
MX336280B (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
NZ738100A (en) Igfbp3 and uses thereof
WO2015164747A8 (en) Methods for diagnosing celiac disease using circulating cytokines/chemokines
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
MX2017000840A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer.
MX2016004167A (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.
MX2016009490A (es) Ensayo novedoso para detectar periostina humana.
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
MX384921B (es) Métodos y sistemas para distinguir el síndrome del intestino irritable de la enfermedad inflamatoria intestinal y la enfermedad celíaca.
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
MX2016016994A (es) Metodos para tratar, diagnosticar y pronosticar una malignidad hematologica.
MA40636A (fr) Procédés pour détecter le cancer de la prostate
MX379289B (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.
WO2014071218A3 (en) Biomarkers for breast cancer and methods of using same
BR112016003058A2 (pt) composições e métodos para análise multiplex de ácidos nucleicos nras e braf
MX2018000189A (es) Metodo para el diagnostico de la enfermedad de farber.